How Lipid Nanoparticle (LNP) Technology Meets The Delivery Need Of Breakthrough saRNA Vaccine
![Doctor Preparing Injection Site GettyImages-1379313214 Doctor Preparing Injection Site GettyImages-1379313214](https://vertassets.blob.core.windows.net/image/bda32e04/bda32e04-8a37-4979-a016-cba1b089a41c/375_250-doctor_preparing_injection_site_gettyimages_1379313214.jpg)
RNA vaccines are hugely versatile. They can potentially inoculate against any pathogen for which a protein target is known. Self-amplifying RNA (saRNA) maintains the advantages of mRNA vaccines but requires a lower dose of RNA due to its self-replicative properties. This reduces the burden of manufacturing, allowing facilities to make 100x more doses than with mRNA due to the reduced cost and time required. As a result, distributed/decentralized manufacturing and quick mass immunizations are possible in the event of a pandemic.
Explore challenges to the successful development of RNA-based drugs and vaccines as well as the advantages of utilizing lipid nanoparticle technology as a delivery platform for saRNA.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.